Jeffrey Hamilton / Getty Images
Three times a week, 66-year-old Tod Gervich injects himself with Copaxone, a prescription drug that can reduce the frequency of relapse in people who have some forms of multiple sclerosis. Having lived with the disease for more than 20 years, the self-employed finance planner in Mashpee, Mass., Is unwilling to manage his condition. What he can't get used to is how Medicare's cohabitation charges put a strain on his wallet.
Unlike commercial plans that cap members are out of pocket medicine costs annually, Medicare has no limits to prescription drugs in Part D, its drug service. Increasing the cost of specialty drugs, some Medicare recipients can blame thousands of dollars in poor drug costs each year for a single drug.
The latest Trump administration proposals and Sen. Ron Wyden, D-Ore., Would address the long-standing problem of introducing a spending ceiling. But it is unclear whether any of these proposals will gain a foothold.
The introduction of Medicare prescription drug distribution in 2006 was a boon to seniors, but coverage had weak points. One was the so-called donut hole – the gap payments came in after they accumulated a few thousand dollars in drug costs and were then hooked on the full cost of their medication. Another was the lack of annual coverage of drug costs.
Legislative changes have gradually closed the donut hole, so that the recipients this year no longer face a cover gap. In a standard Medicare drug plan, recipients pay 25 percent of the price of their branded goods until they reach $ 5,100 in out-of-pocket costs. When patients reach this threshold, the catastrophic portion of their coverage comes in and their commitment drops to 5 percent. But it never disappears.
It is the ongoing 5 percent who hit hard for people like Gervich who take expensive medicine.
His 40 milligram dose of Copaxone costs about $ 75,000 a year, according to the National Multiple Sclerosis Society. In January, Gervich paid $ 1,800 for the drug, and he paid another $ 900 in February. Discounts that drug manufacturers must provide for Part D signups are also counted with his out-of-pocket costs. (More on that later.) In March, he had hit the $ 5,100 threshold that pushed him into disastrous coverage. For the rest of the year, he will owe $ 295 a month for this drug until the cycle starts again in January.
The $ 295 is far from the approx. 6,250 monthly Copaxone price without insurance. But in combination with the $ 2,700 he had already paid before his disastrous coverage kicked in, the extra $ 2,950 he owes this year is not a small amount. And it assumes he doesn't need other drugs.
"I want to be penalized financially for having a chronic illness," he says. He has considered interrupting Copaxone to save money.
His bill of materials is one of the reasons why Gervich has decided not to retire yet, he says, adding that an annual cap on his out-of-pocket costs "would definitely help."  Drugs such as Copaxone, which can alter the effects of the disease, have been on a rising price trend in recent years, says Bari Talente, executive vice president of advocacy at the National Multiple Sclerosis Society. Drugs that cost $ 60,000 annually now cost $ 90,000, she says. With these totals, Medicare beneficiaries will hit catastrophic coverage no matter what. Particularly differentiated drugs for multiple sclerosis, cancer and other conditions – defined by Medicare as those costing more than $ 670 a month – account for more than 20 percent of total spending in Part D plans, up from about 6 percent by 2010, according to a report from the Medicare Payment Advisory Commission, a non-partisan agency advising the program on the program.
Just over 1 million Medicare recipients in Part D plans who did not receive low income support had drug costs That shot them to catastrophic coverage in 2015 – more than twice in 2007 overall – according to an analysis by the Kaiser Family Foundation.
"When drug benefit was created, 5 percent probably didn't seem as big a deal," says Juliette Cubanski , Associate Director of the Medicare Policy Program at the Kaiser Family Foundation. "Now we have such expensive drugs and many of them are covered under Part D – where before there were many expensive drugs r were cancer drugs, which were administered in medical offices and covered by other parts of Medicare.
The lack of a spending limit for Medicare drug benefit sets it apart from other cover. According to the Affordable Care Act, the maximum amount that a person normally owes outside the pocket of covered drugs and other medical care this year is $ 7,900. Plans typically pay 100 percent of customer costs after that.
The Medicare program does not have an out-of-pocket expense limit for Part A or Part B, respectively, covering hospital and ambulatory services, respectively. However, recipients can purchase additional Medigap plans, some of which pay coin security amounts and set pockets payment limits. Medigap plans, however, do not cover part D prescription plans.
Counterbalancing the administration's proposal to impose a spending ceiling on prescription drugs is another suggestion that could increase the number of recipients who do not need the drug. 19659008] Currently, brand names that receive, received, are discounted by 70 percent of manufacturers when Medicare beneficiaries have accumulated at least $ 3,820 in drug costs and until they reach $ 5,100 in out-of-pocket costs. These discounts apply to the recipients' total expenses outside their pocket, which move them faster against disastrous coverage.
Under the administration's proposal, production rebates will no longer be dealt with in this way. The administration says this would help manage patients against cheaper generic drugs.
Still, beneficiaries have to pay more out of pocket to reach the catastrophic cost threshold. Thus, fewer people would probably reach the disastrous level of coverage where they could benefit from an expense coverage.
"Our concern is that some people will pay more outside their pocket to reach the threshold of $ 5,100 and the drug," said Keysha Brooks-Coley, vice president of federal affairs at the American Cancer Society Cancer Action Network.
"It's a bit of a mixed bag," Cubanski says about the proposed calculation change. "There will be savings for some individuals" that reach the disastrous stage of coverage. "But for many there will be higher costs."
For some people, especially cancer patients taking chemotherapy pills, the lack of medical expense coverage in Part D coverage may seem particularly unfair.
These groundbreaking targeted oral chemotherapy and other drugs tend to be expensive, and Medicare beneficiaries often hit the catastrophic threshold quickly, Brooks-Coley says.
Patty Armstrong-Bolle, a Medicare patient living in Haslett, Mich., Takes fire, a pill, once a day to help keep control of breast cancer that has spread to other parts of her body. While the medication has helped to send her cancer into remission, she can never be free of a financial commitment to the precious substance.
Armstrong-Bolle paid $ 2,200 for the drug in January and February last year. When she entered the catastrophic coverage part of her part D plan, the price dropped to $ 584 per month. Armstrong-Bolle's husband died last year and she spent the money from her life insurance policy to cover her drug bills.
This year, a patient care program has covered the first few months of co-insurance. This money runs out next month and she owes her $ 584 again.
If she gets traditional drug infusions instead of taking oral medication, treatment will be covered under part B of the program and her co-insurance payments can be covered.
"It just doesn't seem to be fair," she says.
Kaiser Health News, a nonprofit news service, is an editorial independent program from the Kaiser Family Foundation. Neither KHN nor KFF are affiliated with Kaiser Permanente. Michelle Andrews is on Twitter: @ mandrews110 .